the beauty evolution: from appearance correction to systemic longevity

Last week, I attended In-Cosmetics Global 2026 in Paris. It was a dynamic, exciting event with industry leaders showcasing new insights and breakthrough science and actives. 

Amongst the incredible display of new products and materials and a packed programme of talks, a clear theme emerged: beauty is moving away from surface-level correction towards deep, mechanism-driven skin/hair optimisation and health. 

While this evolution from ‘Anti-Aging’ to ‘Longevity’ has been simmering for years, it now feels like the industry standard. The focus has moved beyond chemistry-led correction of outer visible “signs” to biology-led support for long-term skin function with beauty now seen as a visual manifestation of systemic health. 

implications for R&D

In this review, I’ll capture some key take-aways and, while it’s hard to boil down such a diverse conference, there are some clear strategic implications for R&D:

• Think biological and molecular, not just chemical. 
• Build truly multi-disciplinary teams with many scientific disciplines to develop breakthrough actives and products of the future.
• As teams become more diverse in skill set, invest in proven frameworks and approaches that can align and direct the innovation efforts.  
• Invest not only in actives and products, but also on methods/measures as consumers seek distinctive yet credible data and work closely with regulatory and legal to ensure compliance.  
• Science + Storytelling will be the key to differentiation in a crowded market.

7 key take-aways… and what this means for innovators in beauty

1. The Paradigm Shift: Beauty as a Manifestation of Health 

The most significant takeaway is the total pivot from appearance-based metrics to healthspan and longevity.  Consumers are showing a shift in aspirations towards wanting to live well and feel good, with beauty as the outcome of this.  At an insightful talk from Emilie Hood at Euromonitor, we heard how there is a move away from reactive ‘anti-aging’ towards a more proactive mindset focused on biological health and resilience. 

Consumers are increasingly patient, willing to wait for visible results if they are confident that the product is supporting skin resilience and cellular health at a fundamental level. 

Visual outcomes like hydration, fewer wrinkles, pigmentation and tone are now considered ‘symptoms’ of a healthy biological system rather than standalone targets. 

2. The Rise of the Biological “Mechanism-Literate” Consumer 

Every consumer now has the ability to become an expert with a wealth of data at their fingertips, and they are more literate than ever about ingredients and, increasingly, about mechanisms.  They are no longer just looking for a hero ingredient but also wanting to understand the biological mechanism of action. 

Concepts that were once emergent are now firmly mainstream, such as barrier resilience, cellular repair capacity, microbiome, inflammaging, cellular energy, senescence, biological age (vs chronological age) and mitochondrial dysfunction.  These are now commonly discussed as product actions and can be researched online. 

And this is happening beyond just skin care. K18’s Suveen Sahib and Rita El Khouri confirmed their focus on a “biology-first” approach that aims to address premature biological aging of hair at a systemic level (not just induced damage), leading to resilience and a longer “healthspan” of hair. 

3. The Convergent Beauty Ecosystem: Wellness and Beauty 

Another key theme was the continued blurring of beauty and wellness.  As consumers aspirations now target “living well” and longevity, they are increasingly considering lifestyle as a support for beauty and hair health. 

This means that exercise, sleep, social wellness and nutrition are all connected in the pursuit of “living well”, alongside beauty. After all, if beauty is a manifestation of wellness, a multi-faceted approach is the only logical path. 

Leo Salvi-Sifnaios of The Good Pill Co and Henrik Geertz-Hansen or 21^st BIO picked up on this thread, describing visible beauty as the downstream expression of internal physiology.  This is driving consumer behaviours and underpinning a strong growth path for “ingestible beauty” or nutri-cosmetics. 

With this comes a heightened demand for proof, transparency and clear ingredient evidence, as well as a challenge to deliver formats that can drive a daily ritual in this new frontier of beauty care. 

4. The R&D Evolution: From Chemistry to Multi-Disciplinary Biology 

In the context of this beauty evolution, R&D focus is clearly on identifying and developing precision actives that influence how skin or hair behaves at a cellular and molecular level. 

This has implications for what an R&D team looks like with beauty care no longer being primarily an arena for formulation chemists. The new R&D team spans a broad range of skills, bringing together biology, bioinformatics, genomics, proteomics and metabolomics – alongside formulators who can translate this into stable, sensorially-delightful products. 

Dr. Nava Dayan explained the emerging role of metabolomics in developing skin care actives, while many other talks covered precision approaches to systemic skin and hair intervention. 

Dr Fred Zülli from Mibelle Biochemistry introduced ingredients designed to reset the skin’s epigenetic clock, while Henrique Marconi and Rafael Biscaro from Chemyunion demonstrated actives that modulate melanogenesis – reducing hyperpigmentation in skin while promoting pigmentation in hair follicles to address greying. 

Many of these breakthrough actives are emerging from precision biotech approaches using natural sources, for example, microalgae-derived actives from Algaktiv and fermentation platforms from players like Cellugy and even as new directions from food players like LeSaffre. 

5. Boosting Bio-activity: bio-availability and device synergies  

Another key theme was recognising that it is not just about the ingredient but ensuring it gets to where it needs to go.  Bioactive formulations and bioavailability are now critical R&D priorities, both for efficacy and for claims support.  And in line with consumers embracing products beyond topicals, devices are becoming part of the system rather than an add-on. 

This is already leading to more context-specific actives. For example, Croda’s Matrixyl Neolide – a next-gen encapsulated peptide – has demonstrated synergy with microneedling for collagen III increase. 

This is a clear example of claims being designed around device + topical systems, which feels likely to accelerate. 

6. The GLP-1 Opportunity: Targeted Beauty Support and Sensorial Substitution 

Pia Fisher from WGSN presented a compelling view of the growing opportunity linked to increased GLP-1 usage.  As these drugs become more widely used and for longer durations, consumers are undergoing rapid physical transformation, creating specific needs around skin laxity and body reshaping. 

We are already seeing early responses from beauty brands with targeted products (e.g. Buttface’s BBL firming cream) and increased use of tools and devices to support drainage, fascia release and muscle tone. 

While solving specific “problems” arising from GLP-1 usage is part of the story, the data also show that GLP-1 users are increasing spending on beauty and wellness as a form of sensory reward and self-investment as well as to partly to offset side effects. There is an element of hedonic substitution (seeking pleasure beyond food), but also a broader “virtuous cycle” in which people invest more in themselves as they start to feel better about their bodies/ 

This raises interesting portfolio questions for beauty brands about how to design for this growing target, with possibilities from daily support to professional services and even bio-hacking (e.g. BDV by Dr Vali). 

7. Raising the Claims Threshold: Credible Science is Key 

Consumers have more access to and are placing more scrutiny on credible science and testing markers beyond simple before-and-after photography.  This demands that R&D not only create products that fit seamlessly into daily life but also build robust datasets and clear mechanistic logic behind their performance – smoke and mirrors, and the magical “science bit” will no longer cut it.   

This can bring its own challenges. We heard about the complexity of highly individualised microbiome data (as discussed by Dr Oliver Worsley of Sequential) and the challenges of meaningful measurement of new bio-markers, all within the context of an evolving regulatory and legal backdrop to these emergent claims spaces.  Navigating this changing environment will require solid science and expert narrative development in equal measure. 

Written by Suzanne Allers

Get in touch 📧 suzanne.allers@untappedinnovation.com